Advanced in Pure Red Cell Aplasia

Dr. Robert K. Stuart

Hematology Oncology | Transplant Surgery
171 Ashley Ave, 
Charleston, SC 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Pure Red Cell Aplasia
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Stuart is a Hematologist Oncology specialist and a Transplant Surgeon in Charleston, South Carolina. Dr. Stuart is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Transplant Surgery
Licenses
Internal Medicine in SC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Independent Health
  • EPO
  • POS
  • PPO

Locations

171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: SEA-CD70
Study Phase: Phase 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Drug
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Lenalidomide
Study Phase: Phase 3
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Cytarabine, Vosaroxin
Study Phase: Phase 2
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: November 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Enrollment Status: Unknown
Publish Date: June 29, 2017
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

49 Total Publications

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Journal: Blood advances
Published: May 21, 2024
Similar Doctors
Experienced in Pure Red Cell Aplasia
Dr. Charles S. Holladay
Hematology Oncology | Hematology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Charles S. Holladay
Hematology Oncology | Hematology | Oncology

Bon Secours St Francis Xavier Hospital Inc

2910 Tricom St, 
N Charleston, SC 
 (14.9 miles away)
843-572-9211
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charles Holladay is a Hematologist Oncology specialist and a Hematologist in N Charleston, South Carolina. Dr. Holladay is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Hemochromatosis, Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). Dr. Holladay is currently accepting new patients.

Experienced in Pure Red Cell Aplasia
Dr. Charles S. Greenberg
Hematology | Hematology Oncology | Oncology
Experienced in Pure Red Cell Aplasia
Dr. Charles S. Greenberg
Hematology | Hematology Oncology | Oncology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Greenberg is a Hematologist and a Hematologist Oncology provider in Charleston, South Carolina. Dr. Greenberg is rated as a Distinguished provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Thrombocytopenia, Pulmonary Embolism, Autoimmune Hemolytic Anemia, Antiphospholipid Syndrome, and Bone Marrow Aspiration. Dr. Greenberg is currently accepting new patients.

Experienced in Pure Red Cell Aplasia
Dr. Alexander R. Coltoff
Hematology Oncology | Infectious Disease
Experienced in Pure Red Cell Aplasia
Dr. Alexander R. Coltoff
Hematology Oncology | Infectious Disease

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Experience:
9+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Coltoff is a Hematologist Oncology specialist and an Infectious Disease provider in Charleston, South Carolina. Dr. Coltoff has been practicing medicine for over 9 years and is rated as an Advanced provider by MediFind in the treatment of Pure Red Cell Aplasia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Coltoff is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stuart's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 24 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile